Clinical Edge Journal Scan

Comorbidity rates higher with PsA than psoriasis alone


 

Key clinical point: Patients with psoriatic arthritis (PsA) are more likely to have additional medical conditions beyond skin and joints than those with psoriasis alone.

Major finding: During follow-up, 12% of patients had an indication for PsA. Rates of comorbidities like hypertension, hyperlipidemia, fatigue, diabetes, chronic pulmonary disease, obesity, cardiovascular disease, depression, and anxiety were at least 1.1-1.7 times higher in the psoriasis-PsA vs. psoriasis-only group.

Study details: This was a retrospective study of 19,333 patients with prevalent psoriasis with no prior evidence of PsA from the United States.

Disclosures: The study was funded by UCB Pharma. R Suruki and E Lee declared being employees and shareholders of UCB Pharma. M Skornicki, P Prince, and A Louder declared being employees of Aetion Inc.

Source: Skornicki M et al. Adv Ther. 2021 Apr 5. doi: 10.1007/s12325-021-01698-7.

Recommended Reading

Rheumatology clinics find success with smoking cessation referral program
MDedge Rheumatology
Most patients with chronic inflammatory diseases have sufficient response to COVID-19 vaccination
MDedge Rheumatology
Boosting the presence of darker skin in rheumatology education
MDedge Rheumatology
Debate: Should biologics be used for milder cases of psoriasis?
MDedge Rheumatology
Psoriasis associated with an increased risk of COVID-19 in real-world study
MDedge Rheumatology
Safety and efficacy of upadacitinib in patients refractory to nonbiologic DMARDs
MDedge Rheumatology
OPAL Balance trial confirms long-term safety and efficacy of tofacitinib
MDedge Rheumatology
Guselkumab yields higher enthesitis resolution rates
MDedge Rheumatology
Comparative efficacy of guselkumab, IL-17A, and TNF inhibitors
MDedge Rheumatology
PsA: Women have more severe disease than men
MDedge Rheumatology